Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tandem Diabetes Care Inc. (TNDM:NASDAQ), powered by AI.
Tandem Diabetes Care Inc. is currently trading at $16.69. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Tandem Diabetes Care Inc. on Alpha Lenz.
Tandem Diabetes Care Inc.'s P/E ratio is -5.5.
“Tandem Diabetes Care Inc. trades at a P/E of -5.5 (undervalued) with modest ROE of -97.9%.”
Ask for details →Tandem Diabetes Care Inc. is a medical device company specializing in the design and manufacturing of innovative insulin delivery systems. The company's primary focus is on products intended for diabetes management, making significant contributions to the healthcare sector. Tandem's flagship product, the t:slim X2 insulin pump, is known for its compact size, user-friendly interface, and advanced features such as Bluetooth connectivity and compatibility with continuous glucose monitoring systems. This technology aids in precise and efficient blood sugar control, enhancing the quality of life for diabetes patients. Tandem Diabetes Care plays a pivotal role in the diabetes care market by providing cutting-edge solutions that cater to an unmet medical need, collaborating with healthcare providers to improve patient outcomes. Established in the United States, Tandem's advancements underline its commitment to leveraging technology to foster better health management, setting industry standards for modern diabetes care.
“Tandem Diabetes Care Inc. trades at a P/E of -5.5 (undervalued) with modest ROE of -97.9%.”
Ask for details →Tandem Diabetes Care Inc. (ticker: TNDM) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 2,650 employees. Market cap is $1.1B.
The current price is $16.69 with a P/E ratio of -5.49x and P/B of 7.24x.
ROE is -97.88% and operating margin is -16.49%. Annual revenue is $1.0B.